Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab

Affiliations

¹ From the Department of Neurology (N.P.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; and the Institute of Clinical Neurosciences (N.J.S.), University of Bristol, Frenchay Hospital, UK. robertsonnp@cf.ac.uk.
² From the Department of Neurology (N.P.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; and the Institute of Clinical Neurosciences (N.J.S.), University of Bristol, Frenchay Hospital, UK.

Editorial

Neil P Robertson et al. Neurology. 2014.

. 2014 Jun 17;82(24):2150-1.

doi: 10.1212/WNL.0000000000000530. Epub 2014 May 16.

¹ From the Department of Neurology (N.P.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; and the Institute of Clinical Neurosciences (N.J.S.), University of Bristol, Frenchay Hospital, UK. robertsonnp@cf.ac.uk.
² From the Department of Neurology (N.P.R.), Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales; and the Institute of Clinical Neurosciences (N.J.S.), University of Bristol, Frenchay Hospital, UK.

No abstract available

Comment on

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, Jones J. Kousin-Ezewu O, et al. Neurology. 2014 Jun 17;82(24):2158-64. doi: 10.1212/WNL.0000000000000520. Epub 2014 May 16. Neurology. 2014. PMID: 24838790 Free PMC article. Clinical Trial.